Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Update

Fractyl Health, Inc. (NASDAQ:GUTS) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 3,100,000 shares, an increase of 29.2% from the January 31st total of 2,400,000 shares. Currently, 15.1% of the company’s shares are sold short. Based on an average daily volume of 327,700 shares, the days-to-cover ratio is currently 9.5 days.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley decreased their target price on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd.

Fractyl Health Price Performance

Shares of GUTS traded up $0.02 during mid-day trading on Thursday, hitting $1.61. The company’s stock had a trading volume of 89,344 shares, compared to its average volume of 306,072. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The firm has a 50-day moving average price of $1.76 and a 200 day moving average price of $2.27. Fractyl Health has a fifty-two week low of $1.37 and a fifty-two week high of $9.66. The stock has a market capitalization of $77.44 million and a price-to-earnings ratio of -0.13.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.08). On average, research analysts predict that Fractyl Health will post -1.61 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Jay David Caplan sold 22,346 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.81, for a total value of $40,446.26. Following the completion of the transaction, the insider now directly owns 153,544 shares in the company, valued at approximately $277,914.64. This represents a 12.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Harith Rajagopalan sold 90,972 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.82, for a total transaction of $165,569.04. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $894,218.78. This trade represents a 15.62 % decrease in their position. The disclosure for this sale can be found here.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors and hedge funds have recently modified their holdings of GUTS. Geode Capital Management LLC increased its stake in Fractyl Health by 166.5% in the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock worth $1,269,000 after purchasing an additional 313,335 shares in the last quarter. Blackstone Inc. acquired a new stake in shares of Fractyl Health in the fourth quarter valued at about $212,000. Norges Bank bought a new stake in shares of Fractyl Health in the fourth quarter valued at approximately $206,000. Conservest Capital Advisors Inc. bought a new position in Fractyl Health during the fourth quarter valued at about $132,000. Finally, State Street Corp increased its stake in Fractyl Health by 129.4% in the third quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after acquiring an additional 63,968 shares during the period.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.